Premium
Diffuse neonatal hemangiomatosis in a very low‐birthweight infant treated with erythropoietin
Author(s) -
Okuno Takashi,
Tokuriki Shuko,
Yoshino Tomomi,
Tanaka Nanae,
Ohshima Yusei
Publication year - 2015
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/ped.12517
Subject(s) - medicine , erythropoietin , discontinuation , anemia , concomitant , hemangioma , gestation , propranolol , pediatrics , surgery , pregnancy , biology , genetics
Diffuse neonatal hemangiomatosis ( DNH ) is a rare condition characterized by the concomitant development of multiple cutaneous infantile hemangiomas ( IH ) and visceral hemangiomas. Recently, an association between erythropoietin treatment and an increased incidence of infantile hemangioma was noted. A J apanese male infant was born via cesarean section at 27 weeks of gestation. Following the commencement of erythropoietin treatment for anemia of prematurity, he developed multiple cutaneous hemangiomas, high cardiac output heart failure and hepatomegaly. Abdominal imaging indicated comorbidity of diffuse infantile hepatic hemanigomas, resulting in the final diagnosis of DNH . The discontinuation of erythropoietin treatment and long‐term therapy with propranolol improved the hepatic lesions and cutaneous hemangiomas. The possibility of multiple organ involvement and the exacerbating effects of erythropoietin treatment should be considered in cases in which multiple cutaneous hemangiomas develop in preterm infants receiving erythropoietin treatment.